Bliss GVS Pharma Ltd

Bliss GVS Pharma Limited trading window closed from October 01, 2026 till completion of 48 hours after the announcement of the Unaudited Financial Results for the quarter and half year ended September 30, 2026 generally made available to the public.

Meeting Details

• Board meeting scheduled for October 01, 2026 at the registered office via video conferencing.
• Time of meeting not disclosed.

Key Agenda Items

• Establishment of Senior Executive Employee Stock Option Plan 2026.
• Establishment of Employee Stock Option Plan 2026.

Other Notes

• No additional material notes disclosed.

Promoter reclassification and compliance

• Outgoing Promoters ceased to be in control; pre-completion 34.82% held by 25 entities, post 0.01%.
• Promoter reclassification to public under Regulation 31A(10) of the SEBI Listing Regulations.
• Open offer completed; Purchaser/PAC acquired control of the company.
• SPA dated May 23, 2026; DOA dated July 17, 2026; PAC assigned rights.
• LOF disclosures to Incoming Promoter; company complies with Reg 31A(3)(b) and 31A(4).

Promoter change and shareholding

• PAC and Purchaser hold 47.95% post Open Offer.
• Promoter status conferred to Anupam Rasayan India Ltd and PAC.

Director appointments

• Hetul Krishnakant Mehta appointed Additional Director (Non-Executive Non-Independent) effective Sep 28, 2026.
• Amar Dilip Shah appointed Additional Director (Non-Executive Non-Independent) effective Sep 28, 2026.
• Pramod Badrinarayan Kasat appointed Additional Director (Non-Executive Non-Independent) effective Sep 28, 2026.

MD resignation

• Mr. Narsimha Shibroor Kamath resigns as Managing Director effective Sep 28, 2026.

Shareholder voting and approvals

• Draft Postal Ballot Notice approved for appointment of three Non-Executive Non-Independent Directors.

Resolution and outcome

• Appointment of Santosh Parab (DIN: 01622988) as Non-Executive, Non-Independent Director (Ordinary Resolution).
• Term not disclosed; no director experience details provided in extract.
• Voting: 97.04% in favour, 2.96% against; total votes polled 10,62,43,972.
• Voting period Aug 21–Sep 19, 2026; Cut-off date Aug 14, 2026.
• No change in share capital or other material corporate actions.

Open offer overview

• Acquirer and PAC to buy up to 2,77,26,848 shares, 26% of voting capital.
• Offer price ₹299 per share; maximum consideration ₹829,03,27,552 on full acceptance.
• Open offer opened on 28 July 2026 and closed on 10 August 2026.
• Post-offer combined holding of Acquirer and PAC would be 2,79,22,179 shares (26.18%).
• Base acquisition under SPA: 4,58,03,024 shares (~43%), with option for up to 51,81,571 residual shares.
• PAC designated as person acting in concert after Acquirer’s acquisition of Mates Visa.
• Underlying transaction to be consummated within SEBI SAST timeframe; completion pending.
• Tendered shares: 2,77,26,848; accepted: 2,77,26,848; prior open-offer acquisition: 1,669 shares.
• Post-offer advertisement issued by SBI Capital Markets Limited as Manager to the Offer.
• Underlying transaction scope remains subject to statutory approvals and regulatory conditions.

Resolutions

• Ordinary Resolution: Appointment of Santosh Parab as Non-Executive Non-Independent Director.
• E-voting window: August 21, 2026 to September 19, 2026.
• Cut-off date for eligibility: August 14, 2026.
• Outcome: Pending; results to be announced by Sep 22, 2026.
• Scrutinizer appointed: Vijay Yadav.
• Profile: Santosh Parab, CA; DIN 01622988; 35+ years in audit.
• Term: liable to retire by rotation; appointment as Additional Director w.e.f. July 3, 2026.
• Impact: governance shift with one additional director; no capital actions.